[ad_1]
(Reuters) – British pharmaceutical group Vectura Group Plc said Saturday it won a patent infringement suit against GlaxoSmithKline Plc in the US and got $ 89.7 million in damages for the period from August 2016 to December 2018.
A jury trial in a Delaware district court on Friday revealed that one of Vectura's US patents had been infringed by the sale of three of GSK Ellipta's products in the United States, Vectura added.
The jury found that GSK, which is also a UK-based pharmaceutical company, deliberately infringed the patent, which, according to Vectura, gave it the right to claim additional damages.
Vectura plans to apply for the 3% royalty on sales of counterfeit products by the end of the patent's patent term in mid-2021, he said.
Vectura commenced legal proceedings against GSK in July 2016 after the expiry of a patent license agreement between the two companies and GSK refused to license any other patent families under of the initial contract.
GSK has not responded to Reuters requests for comment outside of normal business hours.
Report by Ishita Chigilli Palli in Bengaluru; edited by Diane Craft
Source link
